Gill KL, Machavaram KK, Rose RH, Chetty M (2016) Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet 55:789–805. https://doi.org/10.1007/s40262-015-0361-4

Article  CAS  PubMed  Google Scholar 

Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14(2):296–302. https://doi.org/10.1208/s12248-012-9340-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T (2011) Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70:1208–1215. https://doi.org/10.1136/ard.2011.153023

Article  CAS  PubMed  Google Scholar 

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 55:1381–1394. https://doi.org/10.1007/s40262-016-0406-3

Article  CAS  PubMed  Google Scholar 

Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D (2005) Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 52:2693–2696. https://doi.org/10.1002/art.21266

Article  CAS  PubMed  Google Scholar 

Julià M, Guilabert A, Lozano F, Suarez-Casasús B, Moreno N, Carrascosa JM, Ferrándiz C, Pedrosa E, Alsina-Gibert M, Mascaró JM Jr. (2013) The role of Fcγ receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol 149:1033–1039. https://doi.org/10.1001/jamadermatol.2013.4632

Article  CAS  PubMed  Google Scholar 

Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW (2019) A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 7:192. https://doi.org/10.1186/s40425-019-0669-y

Article  PubMed  PubMed Central  Google Scholar 

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS (2017) Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 16:2215–2222. https://doi.org/10.1158/1535-7163.MCT-16-0895

Article  CAS  PubMed  Google Scholar 

Yamasaki K, Chuang VT, Maruyama T, Otagiri M (2013) Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 1830:5435–5443. https://doi.org/10.1016/j.bbagen.2013.05.005

Article  CAS  PubMed  Google Scholar 

Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RG, Sukhai RN (2015) Pharmacokinetics of Rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol 30:1367–1370. https://doi.org/10.1007/s00467-015-3120-8

Article  PubMed  PubMed Central  Google Scholar 

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel therapies for resistant FSGS) study group. Am J Kidney Dis 55:50–60. https://doi.org/10.1053/j.ajkd.2009.08.019

Article  CAS  PubMed  Google Scholar 

Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS (2019) Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother 53:357–363. https://doi.org/10.1177/1060028018803587

Article  CAS  PubMed  Google Scholar 

Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP (2012) Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 7:203–211. https://doi.org/10.1097/JTO.0b013e3182370e02

Article  CAS  PubMed  Google Scholar 

Piscitani L, Sirolli V, Di Liberato L, Morroni M, Bonomini M (2020) Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations. Int J Mol Sci 21. https://doi.org/10.3390/ijms21144878

Iwamoto N, Shimada T, Umino Y, Aoki C, Aoki Y, Sato TA, Hamada A, Nakagama H (2014) Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis. Analyst 139:576–580. https://doi.org/10.1039/c3an02104a

Article  CAS  PubMed  Google Scholar 

Iwamoto N, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T (2016) Fully validated LCMS bioanalysis of bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Drug Metab Pharmacokinet 31:46–50. https://doi.org/10.1016/j.dmpk.2015.11.004

Article  CAS  PubMed  Google Scholar 

Iwamoto N, Shimada T, Terakado H, Hamada A (2016) Validated LC-MS/MS analysis of immune checkpoint inhibitor nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. J Chromatogr B Analyt Technol Biomed Life Sci 1023–1024:9–16. https://doi.org/10.1016/j.jchromb.2016.04.038

Article  CAS  PubMed  Google Scholar 

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786. https://doi.org/10.1007/s00280-007-0664-8

Article  CAS  PubMed  Google Scholar 

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacomet Syst Pharmacol 6:58–66. https://doi.org/10.1002/psp4.12143

Article  CAS  Google Scholar 

Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D (2014) Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457–470. https://doi.org/10.1038/ki.2013.344

Article  CAS  PubMed  Google Scholar 

Bazzi C, Petrini C, Rizza V, Arrigo G, D’Amico G (2000) A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 58:1732–1741. https://doi.org/10.1046/j.1523-1755.2000.00334.x

Article  CAS  PubMed  Google Scholar 

Taylor GM, Neuhaus TJ, Shah V, Dillon S, Barratt TM (1997) Charge and size selectivity of proteinuria in children with idiopathic nephrotic syndrome. Pediatr Nephrol 11:404–410. https://doi.org/10.1007/s004670050305

Article  CAS  PubMed  Google Scholar 

Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A, RITERM study group (2021) Rituximab in membranous nephropathy. Kidney Int Rep 6:881–893. https://doi.org/10.1016/j.ekir.2020.12.035

Article  PubMed  PubMed Central  Google Scholar 

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930

Article  CAS  PubMed  Google Scholar 

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779–791. https://doi.org/10.1016/S1470-2045(17)30279-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Wa